問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chi Mei Hospital, Liouying (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Chi Mei Medical Center (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Chi Mei Medical Center

更新時間：2023-09-19

高婉真
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

103Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

高婉真

Chi Mei Hospital, Liouying

Division of Hematology & Oncology

List

81Cases

2020-02-28 - 2022-12-31

Phase II

A Phase 2, open-label study of orally administered PAX-1 therapy in patients with brain metastases secondary to non-small cell lung cancer

  • Condition/Disease

    Brain metastases secondary to non-small cell lung cancer

  • Test Drug

    PAX-1

Participate Sites
8Sites

Recruiting8Sites

2019-04-01 - 2022-03-03

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2017-01-06 - 2022-01-05

Phase III

ONO-4538 Phase III Study A multicenter, double-blind, randomized study in patients with gastric cancer undergoing postoperative adjuvant chemotherapy

  • Condition/Disease

    Gastric Cancer

  • Test Drug

    Nivolumab

Participate Sites
10Sites

Terminated8Sites

白禮源
China Medical University Hospital-Taipei

未分科

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2019-01-22 - 2022-07-12

Phase III

A Randomized, Double-blind, Active-controlled, Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Test Drug

    ABP 959

Participate Sites
3Sites

Recruiting3Sites

2020-11-01 - 2022-03-11

Phase II

A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid Tumors

  • Condition/Disease

    Non Small Cell Lung Cancer / Urothelial Cancer / Renal Cell Carcinoma / Hepatocellular Carcinoma / Melanoma

  • Test Drug

    INCB086550

Participate Sites
7Sites

Recruiting3Sites

Terminated4Sites

2019-06-01 - 2021-09-28

Phase II

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    M7824

Participate Sites
5Sites

Recruiting5Sites

2020-05-01 - 2023-01-31

Others

A two-stage, multi-center, open-label, randomized, controlled trial comparing the efficacy and safety of intra-peritoneal infusion of catumaxomab and treatment of investigator choice in patients with advanced gastric carcinoma with peritoneal metastasis

  • Condition/Disease

    advanced gastric carcinoma with peritoneal metastasis

  • Test Drug

    Catumaxomab

Participate Sites
4Sites

Recruiting4Sites

2016-07-31 - 2022-06-30

Phase II/III

A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    ASP2215

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2021-05-20 - 2023-05-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2019-09-01 - 2022-12-31

Phase II

A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)

  • Condition/Disease

    Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies

  • Test Drug

    ME-401

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB